Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
-
REGULATORY PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
-
BUSINESS MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
-
REGULATORY Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
-
REGULATORY MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
-
REGULATORY Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
-
BUSINESS Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
-
BUSINESS Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
-
REGULATORY Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
-
ORGANIZATION 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
-
BUSINESS Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
-
ORGANIZATION Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
-
BUSINESS Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
-
BUSINESS Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
-
BUSINESS Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
-
BUSINESS Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
-
REGULATORY Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
-
BUSINESS Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
-
BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
-
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…